Skip to main content
< Back to news
Albert Esteve will be appointed Chairman of the Board of Directors to replace Joan Esteve (Photo: Esteve).

Esteve closes the Board of Directors renewal process with the appointment of Joan Esteve as a Chairman

Esteve has just announced changes to its corporate governing bodies. In line with the plan approved by the Group's Board, Albert Esteve will replace Joan Esteve as Chairman of the Board and announces the appointment of Staffan Schüberg, executive vicepresident of the Danish pharmaceutical company Lundbeckas, the group's Chief Executive Officer. Since 2012, all discovery and preclinical development key units of Esteve are located at the Barcelona Science Park with the latest infrastructure and technology in a top-level academic and scientific environment in Spain.


Albert Esteve, CEO and Vice-Chairman of the group, will assume the Chairmanship in January 2018, “This is a new challenge that I am facing with tremendous enthusiasm. Consolidating the best practices in corporate governance initiated under the leadership of Joan Esteve, preserving the values that he has always defended and have been his norm of action in the Board and to support the growth of the group are my priorities”. 

Joan Esteve, who assumed the presidency of the group in 2012, a critical transition period for the company, managed to reverse the negative trend and return the company to a sustainable growth path. In these five years, Joan Esteve has led some of the most relevant projects of the group, such as a global agreement for the development of several of its own research projects and fostered a globalization of the group with international sales now representing 70% of the group’s sale. 

Staffan Schüberg will join Esteve on January 1, 2018 as Chief Executive Officer (CEO). He will lead the executive management of the Esteve Group of companies, including all of its business activities (chemical, R&D based pharmaceuticals and generics). Schüberg has more than 20 years experience from multinational pharma and is joining from the Danish multinational company Lundbeck where he has held the position as Executive Vice President and Chief Commercial Officer of the group. 

Related news [+]